64724-29-4

Basic information

• Product Name: Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN
• Synonyms: Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN;Z-(1)-Ethoxy-(2)-(tributylstannyl)ethylen ,94%;cis-Tributyl[2-ethoxyethenyl]stannane;cis-1-Ethoxy-2-(tri-n-butylstannyl)ethylene, 94%;tributyl[(Z)-2-ethoxyethenyl]stannane;tributyl((Z)-2-ethoxyvinyl)stannane;)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN;(Z)-1-Ethoxy-2-(tributylstannyl)ethylene
• CAS NO: 64724-29-4
• Molecular Formula: C₁₆H₃₄OSn
• Molecular Weight: 361.15056
• Product Categories: Stannanes
• Mol File: 64724-29-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 84-87℃
• Boiling Point: 345°C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.082
• Vapor Pressure: 0.000127mmHg at 25°C
• Refractive Index: n20/D1.479
• Storage Temp.: 2-8°C
• Water Solubility: Soluble in water.
• CAS DataBase Reference: Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN(CAS DataBase Reference)
• NIST Chemistry Reference: Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN(64724-29-4)
• EPA Substance Registry System: Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN(64724-29-4)

Safety Data

• Hazard Codes: T,N
• Statements: 21-25-36/38-48/23/25-50/53
• Safety Statements: 35-36/37/39-45-60-61
• RIDADR: UN 2788 6.1 / PGIII
• WGK Germany: 3
• HazardClass: 6.1
• Hazardous Substances Data: 64724-29-4(Hazardous Substances Data)

Usage

Uses

cis-1-Ethoxy-2-(tri-n-butylstannyl)ethylene is widely used in pharmaceutical research and as reagent.

InChI:InChI=1/C4H7O.3C4H9.Sn/c1-3-5-4-2;3*1-3-4-2;/h1,3H,4H2,2H3;3*1,3-4H2,2H3;/rC16H34OSn/c1-5-9-13-18(14-10-6-2,15-11-7-3)16-12-17-8-4/h12,16H,5-11,13-15H2,1-4H3/b16-12-

Upstream product

• 688-73-3 tri-n-butyl-tin hydride 
• 927-80-0 1-ethoxyacetylene 
• 23521-49-5 (Z)-1-bromo-2-ethoxyethene 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 111477-34-0 (Z)-1-(2-ethoxyethenyl)-4-nitrobenzene 
• 143101-62-6 (E)-3-ethoxy-1-(4-nitrophenyl)prop-2-en-1-one 
• 31026-82-1 (Z)-1-(2-ethoxyvinyl)-4-methoxybenzene 
• 31172-40-4 (E)-3-ethoxy-1-phenylprop-2-ene-1-one 
• 143101-58-0 (E)-3-ethoxy-1-(4-methylphenyl)prop-2-en-1-one 
• 128639-98-5 (Z)-4-(2-ethoxyethenyl)-N,N-dimethylaniline 
• 13466-40-5 (2E, 4E)-5-phenylpenta-2,4-dienal 
• 142-83-6 trans,trans-2,4-Hexadienal 
• 49678-08-2 3-(4-nitrophenyl)-propenal 
• 14371-10-9 (E)-3-phenylpropenal 
• 176327-47-2 N-(benzenesulfonyl)-3-(2-ethoxyethenyl)indole-2-carboxaldehyde 
• 226903-38-4 (Z)-1-ethoxy-6-(p-methoxyphenoxy)-1-hexen-3-one 
• 1461-25-2 tetra-n-butyltin(IV) 
• 78443-74-0 (E)-3-<2,4-dichloro-6-(phenylmethoxy)phenyl>-2-propenal 

Relevant articles and documents

COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS

The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

HETEROCYCLIC COMPOUNDS

The invention relates to compounds of formula I and salts thereof wherein the substituents are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part